Amyloid Imaging: From Benchtop to Bedside

Current Topics in Developmental Biology

Volumn 70, Issue , 2005, Pages 171-213

  Wu, Chunying ^a,b   Pike, Victor W ^c   Wang, Yanming ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b JIANGSU INSTITUTE OF NUCLEAR MEDICINE   (China)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; ANIMAL; DRUG SCREENING; HUMAN; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW;

ALZHEIMER DISEASE; AMYLOID; ANIMALS; BIOLOGICAL MARKERS; DRUG EVALUATION, PRECLINICAL; HUMANS; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY;

EID: 33645942732     PISSN: 00702153     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0070-2153(05)70008-9     Document Type: Review

References (134)

1. Agdeppa E.D., Kepe V., Liu J., Flores-Torres S., Satyamurthy N., Petric A., Cole G.M., Small G.W., Huang S.C., and Barrio J.R. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J. Neurosci. 21 (2001) RC189
2. Agdeppa E.D., Kepe V., Petri A., Satyamurthy N., Liu J., Huang S.C., Small G.W., Cole G.M., and Barrio J.R. In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malono nitrile. Neuroscience 117 (2003) 723-730
3. Alzheimer A. Ueber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift der Psychiatrie 64 (1907) 146-148
4. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J. Nucl. Med. 42 (2001) 213-221
5. Barrio J.R., Huang S.C., Cole G.M., Satyamurthy N., Petric A., Phelps M.E., and Small G.W. PET imaging of tangles and plaques in Alzheimer's disease with a highly hydrophobic probes. J. Label. Radiopharm. 42 (1999) S194-S195
6. Bickel U., Lee V.M., Trojanowski J.Q., and Pardridge W.M. Development and in vitro characterization of a cationized monoclonal antibody against beta A4 protein: A potential probe for Alzheimer's disease. Bioconjug.Chem. 5 (1994) 119-125
7. 99mTc-radiolabeled annexin V. J. Nucl. Med. 42 (2001) 309-316
8. Blankenberg F.G., and Strauss H.W. Noninvasive strategies to image cardiovascular apoptosis. Cardiol. Clin. 19 (2001) 165-172
9. Blasberg R. PET imaging of gene expression. Eur. J. Cancer 38 (2002) 2137-2146
10. Blasberg R.G., and Gelovani-Tjuvajev J. In vivo molecular-genetic imaging. J. Cell Biochem. 39 Suppl. (2002) 172-183
11. Bresjanac M., Smid L.M., Vovko T.Z., Petric A., Barrio J.R., and Popovic M. Molecular-imaging probe 2-(1-{6-[(2-fluoroethyl)(methyl) amino]-2-naphthyl}ethylidene) malononitrile labels prion plaques in vitro. J. Neurosci. 23 (2003) 8029-8033
12. 18F]fluorodeoxyglucose and positron emission tomography: A pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br. J. Cancer 82 (2000) 608-615
13. Burns J., Pennock C.A., and Stoward P.J. The specificity of the staining of amyloid deposits with thioflavine T. J. Pathol. Bacteriol. 94 (1967) 337-344
14. 18F-labeled 6-iodo-2-(4′-N,N-dimethylamino)phenylimidazo[1,2-a]pyridine derivatives as prospective radioligands for beta-amyloid in Alzheimer′'s disease. J. Med. Chem. 47 (2004) 2208-2218
15. Casciari J.J., Graham M.M., and Rasey J.S. A modeling approach for quantifying tumor hypoxia with [F-18]fluoromisonidazole PET time-activity data. Med. Phys. 22 (1995) 1127-1139
16. Chen C.C., Meadows B., Regis J., Kalafsky G., Fojo T., Carrasquillo J.A., and Bates S.E. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi. Clin. Cancer Res. 3 (1997) 545-552
17. Cherry S.R. Fundamentals of positron emission tomography and applications in preclinical drug development. J. Clin. Pharmacol. 41 (2001) 482-491
18. Clark R.F., and Goate A.M. Pharmacological treatment of Alzheimer's disease. In: Brioni J.D., and Decker M.W. (Eds). "Molecular and Neurobiological Foundations" (1997), Wiley-Liss, New York 193-216
19. De Strooper B., and Konig G. Alzheimer's disease. A firm base for drug development. Nature 402 (1999) 471-472
20. Dehdashti F., Flanagan F.L., Mortimer J.E., Katzenellenbogen J.A., Welch M.J., and Siegel B.A. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur. J. Nucl. Med. 26 (1999) 51-56
21. Delacourte A. Diagnosis of Alzheimer's disease [in French]. Ann. Biol. Clin. (Paris) 56 (1998) 133-142
22. 99mTc-MAMA-chrysamine G, a probe for beta-amyloid protein of Alzheimer's disease. Eur. J. Nucl. Med. 26 (1999) 1392-1399
23. Dishino D.D., Welch M.J., Kilbourn M.R., and Raichle M.E. Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. J. Nucl. Med. 24 (1983) 1030-1038
24. Eckelman W.C. The use of PET and knockout mice in the drug discovery process. Drug Discov. Today 8 (2003) 404-410
25. Foo S.S., Abbott D.F., Lawrentschuk N., and Scott A.M. Functional imaging of intratumoral hypoxia. Mol. Imaging Biol. 6 (2004) 291-305
26. Friedland R.P., Majocha R.E., Reno J.M., Lyle L.R., and Marotta C.A. Development of an anti-A beta monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease. Mol. Neurobiol. 9 (1994) 107-113
27. Friedland R.P., Shi J., Lamanna J.C., Smith M.A., and Perry G. Prospects for noninvasive imaging of brain amyloid beta in Alzheimer's disease. Ann. NY Acad. Sci. 903 (2000) 123-128
28. Gambhir S.S., Barrio J.R., Herschman H.R., and Phelps M.E. Assays for noninvasive imaging of reporter gene expression. Nucl. Med. Biol. 26 (1999) 481-490
29. Gee A.D. Neuropharmacology and drug development. Br. Med. Bull. 65 (2003) 169-177
30. 125I]A beta 1-40 labels amyloid deposits in the aged primate brain in vivo. Neuroreport 7 (1996) 2607-2611
31. Gupta N., Price P.M., and Aboagye E.O. PET for in vivo pharmacokinetic and pharmacodynamic measurements. Eur. J. Cancer 38 (2002) 2094-2107
32. Han H., Cho C.G., and Lansbury Jr. P.T. Technetium complexes for the quantitation of brain amyloid. J. Am. Chem. Soc. 118 (1996) 4506-4507
33. Hardy J. An "anatomical cascade hypothesis" for Alzheimer's disease. Trends Neurosci. 15 (1992) 200-201
34. 123I-labeled serum amyloid P component. J. Exp. Med. 167 (1988) 903-913
35. Hawkins P.N., Myers M.J., Lavender J.P., and Pepys M.B. Diagnostic radionuclide imaging of amyloid: Biological targeting by circulating human serum amyloid P component. Lancet 1 (1988) 1413-1418
36. Hendrikse N.H., de Vries E.G., Eriks-Fluks L., van der Graaf W.T., Hospers G.A., Willemsen A.T., Vaalburg W., and Franssen E.J. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res. 59 (1999) 2411-2416
37. Hendrikse N.H., Franssen E.J., van der Graaf W.T., Vaalburg W., and de Vries E.G. Visualization of multidrug resistance in vivo. Eur. J. Nucl. Med. 26 (1999) 283-293
38. Herschman H.R. Noninvasive imaging of reporter gene expression in living subjects. Adv. Cancer Res. 92 (2004) 29-80
39. Hilbich C., Kisters-Woike B., Reed J., Masters C.L., and Beyreuther K. Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer's disease. J. Mol. Biol. 218 (1991) 149-163
40. Hirschfield G.M., and Hawkins P.N. Amyloidosis: New strategies for treatment. Int. J. Biochem. Cell Biol. 35 (2003) 1608-1613
41. Hume S.P., Brown D.J., Ashworth S., Hirani E., Luthra S.K., and Lammertsma A.A. In vivo saturation kinetics of two dopamine transporter probes measured using a small animal positron emission tomography scanner. J. Neurosci. Methods 76 (1997) 45-51
42. Ikeda S., Wong C.W., Allsop D., Landon M., Kidd M., and Glenner G.G. Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti-beta protein monoclonal antibody. Lab. Invest. 57 (1987) 446-449
43. Ishii K., Tamaoka A., Mizusawa H., Shoji S., Ohtake T., Fraser P.E., Takahashi H., Tsuji S., Gearing M., Mizutani T., Yamada S., Kato M., St George-Hyslop P.H., Mirra S.S., and Mori H. Abeta1-40 but not Abeta1-42 levels in cortex correlate with apolipoprotein E epsilon4 allele dosage in sporadic Alzheimer's disease. Brain Res. 748 (1997) 250-252
44. Ishikawa K., Doh-ura K., Kudo Y., Nishida N., Murakami-Kubo I., Ando Y., Sawada T., and Iwaki T. Amyloid imaging probes are useful for detection of prion plaques and treatment of transmissible spongiform encephalopathies. J. Gen. Virol. 85 (2004) 1785-1790
45. Jacobson A., Petric A., Hogenkamp D., Sinur A., and Barrio J.R. 1,1-Dicyano-2-[6-(dimethylamino)naphthalen-2-yl]propene (DDNP): A solvent polarity and viscosity sensitive fluorophore for fluorescence microscopy. J. Am. Chem. Soc. 118 (1996) 5572-5579
46. Joachim C.L., Morris J.H., and Selkoe D.J. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am. J. Pathol. 135 (1989) 309-319
47. 18F]-setoperone PET imaging. Nucl. Med. Commun. 18 (1997) 395-399
48. 2 receptors: Implications for the therapeutics of schizophrenia. Am. J. Psychiatry 154 (1997) 1525-1529
49. 2 receptor occupancy and plasma levels on low dose oral haloperidol: A PET study. Psychopharmacology (Berl) 131 (1997) 148-152
50. Katzman R. Education and the prevalence of dementia and Alzheimer's disease. Neurology 43 (1993) 13-20
51. Kilbourn M.R., Pavia M.R., and Gregor V.E. Synthesis of fluorine-18 labeled GABA uptake inhibitors. Int. J. Rad. Appl. Instrum. [A] 41 (1990) 823-828
52. Klunk W.E., Bacskai B.J., Mathis C.A., Kajdasz S.T., McLellan M.E., Frosch M.P., Debnath M.L., Holt D.P., Wang Y., and Hyman B.T. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J. Neuropathol. Exp. Neurol. 61 (2002) 797-805
53. Klunk W.E., Debnath M.L., and Pettegrew J.W. Chrysamine-G binding to Alzheimer and control brain: Autopsy study of a new amyloid probe. Neurobiol. Aging 16 (1995) 541-548
54. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergstrom M., Savitcheva I., Huang G.F., Estrada S., Ausen B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., and Langstrom B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55 (2004) 306-319
55. Klunk W.E., Jacob R.F., and Mason R.P. Quantifying amyloid beta-peptide (Abeta) aggregation using the Congo red-Abeta (CR-abeta) spectrophotometric assay. Anal. Biochem. 266 (1999) 66-76
56. Klunk W.E., Pettegrew J.W., and Abraham D.J. Quantitative evaluation of congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J. Histochem. Cytochem. 37 (1989) 1273-1281
57. Klunk W.E., Wang Y., Huang G.F., Debnath M.L., Holt D.P., and Mathis C.A. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci. 69 (2001) 1471-1484
58. Klunk W.E., Wang Y., Huang G.F., Debnath M.L., Holt D.P., Shao L., Hamilton R.L., Ikonomovic M.D., De Kosky S.T., and Mathis C.A. The binding of 2-(4′-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J. Neurosci. 23 (2003) 2086-2092
59. Kung H.F., Kung M.P., Zhuang Z.P., Hou C., Lee C.W., Plossl K., Zhuang B., Skovronsky D.M., Lee V.M., and Trojanowski J.Q. Iodinated tracers for imaging amyloid plaques in the brain. Mol. Imaging Biol. 5 (2003) 418-426
60. Kung H.F., Lee C.W., Zhuang Z.P., Kung M.P., Hou C., and Plossl K. Novel stilbenes as probes for amyloid plaques. J. Am. Chem. Soc. 123 (2001) 12740-12741
61. Kung M.P., Hou C., Zhuang Z.P., Skovronsky D., and Kung H.F. Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease. Brain Res. 1025 (2004) 98-105
62. Kung M.P., Hou C., Zhuang Z.P., Skovronsky D.M., Zhang B., Gur T.L., Trojanowski J.Q., Lee V.M., and Kung H.F. Radioiodinated styrylbenzene derivatives as potential SPECT imaging agents for amyloid plaque detection in Alzheimer's disease. J. Mol. Neurosci. 19 (2002) 7-10
63. Kung M.P., Hou C., Zhuang Z.P., Zhang B., Skovronsky D., Trojanowski J.Q., Lee V.M., and Kung H.F. IMPY: An improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques. Brain Res. 956 (2002) 202-210
64. 111In chelation, conjugation to poly(ethylene glycol)-biotin linkers, and autoradiography with Alzheimer's disease brain sections. Bioconjug. Chem. 11 (2000) 380-386
65. Lashuel H.A., Hartley D.M., Balakhaneh D., Aggarwal A., Teichberg S., and Callaway D.J. New class of inhibitors of amyloid-beta fibril formation. Implications for the mechanism of pathogenesis in Alzheimer's disease. J. Biol. Chem. 277 (2002) 42881-42890
66. Lee C.W., Kung M.P., Hou C., and Kung H.F. Dimethylamino-fluorenes: Ligands for detecting beta-amyloid plaques in the brain. Nucl. Med. Biol. 30 (2003) 573-580
67. Lee H.J., and Pardridge W.M. Pharmacokinetics and delivery of tat and tat-protein conjugates to tissues in vivo. Bioconjug. Chem. 12 (2001) 995-999
68. Lee H.J., Zhang Y., Zhu C., Duff K., and Pardridge W.M. Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical. J. Cereb. Blood Flow Metab. 22 (2002) 223-231
69. 11C-colchicine for PET imaging of multiple drug resistance. J. Nucl. Med. 41 (2000) 493-501
70. Levin V.A. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. 23 (1980) 682-684
71. Le Vine III H. Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 309 (1999) 274-284
72. Levine L.E., Reiss G., and Smith D.A. In situ scanning-tunneling-microscopy studies of early-stage electromigration in Ag. Physical Review. B. Condensed Matter. 48 (1993) 858-863
73. Lewis J.S., Herrero P., Sharp T.L., Engelbach J.A., Fujibayashi Y., Laforest R., Kovacs A., Gropler R.J., and Welch M.J. Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone). J. Nucl. Med. 43 (2002) 1557-1569
74. Link C.D., Johnson C.J., Fonte V., Paupard M., Hall D.H., Styren S., Mathis C.A., and Klunk W.E. Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34. Neurobiol. Aging 22 (2001) 217-226
75. 123I-serum amyloid P component in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 12 (1998) 208-210
76. 123I serum amyloid P component scintigraphy in 484 patients. Gut 42 (1998) 727-734
77. Maggio J.E., Stimson E.R., Ghilardi J.R., Allen C.J., Dahl C.E., Whitcomb D.C., Vigna S.R., Vinters H.V., Labenski M.E., and Mantyh P.W. Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide. Proc. Natl. Acad. Sci. USA 89 (1992) 5462-5466
78. Majocha R.E., Reno J.M., Friedland R.P., Van Haight C., Lyle L.R., and Marotta C.A. Development of a monoclonal antibody specific for beta/A4 amyloid in Alzheimer's disease brain for application to in vivo imaging of amyloid angiopathy. J. Nucl. Med. 33 (1992) 2184-2189
79. Marshall J.R., Stimson E.R., Ghilardi J.R., Vinters H.V., Mantyh P.W., and Maggio J.E. Noninvasive imaging of peripherally injected Alzheimer's disease type synthetic A beta amyloid in vivo. Bioconjug. Chem. 13 (2002) 276-284
80. Mathis C.A., Bacskai B.J., Kajdasz S.T., McLellan M.E., Frosch M.P., Hyman B.T., Holt D.P., Wang Y., Huang G.F., Debnath M.L., and Klunk W.E. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med. Chem. Lett. 12 (2002) 295-298
81. 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J. Med. Chem. 46 (2003) 2740-2754
82. Mathis C.A., Wang Y., and Klunk W.E. Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr. Pharm. Des. 10 (2004) 1469-1492
83. Mochizuki A., Peterson J.W., Mufson E.J., and Trapp B.D. Amyloid load and neural elements in Alzheimer's disease and nondemented individuals with high amyloid plaque density. Exp. Neurol. 142 (1996) 89-102
84. Morris J.C., Storandt M., McKeel Jr. D.W., Rubin E.H., Price J.L., Grant E.A., and Berg L. Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease. Neurology 46 (1996) 707-719
85. Narula J., Acio E.R., Narula N., Samuels L.E., Fyfe B., Wood D., Fitzpatrick J.M., Raghunath P.N., Tomaszewski J.E., Kelly C., Steinmetz N., Green A., Tait J.F., Leppo J., Blankenberg F.G., Jain D., and Strauss H.W. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat. Med. 7 (2001) 1347-1352
86. Naslund J., Haroutunian V., Mohs R., Davis K.L., Davies P., Greengard P., and Buxbaum J.D. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283 (2000) 1571-1577
87. Naslund J., Schierhorn A., Hellman U., Lannfelt L., Roses A.D., Tjernberg L.O., Silberring J., Gandy S.E., Winblad B., Greengard P., Nordstedt C., and Terenius L. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc. Natl. Acad. Sci. USA 91 (1994) 8378-8382
88. Nordberg A. Toward an early diagnosis and treatment of Alzheimer's disease. Int. Psychogeriatr. 15 (2003) 223-237
89. Nutt R. For: Is LSO the future of PET?. Eur. J. Nucl. Med. Mol. Imaging 29 (2002) 1523-1525
90. Okamura N., Suemoto T., Shimadzu H., Suzuki M., Shiomitsu T., Akatsu H., Yamamoto T., Staufenbiel M., Yanai K., Arai H., Sasaki H., Kudo Y., and Sawada T. Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain. J. Neurosci. 24 (2004) 2535-2541
91. Olshansky S.J., Carnes B.A., and Cassel C.K. The aging of the human species. Sci. Am. 268 (1993) 46-52
92. Ono M., Kung M.P., Hou C., and Kung H.F. Benzofuran derivatives as Abeta-aggregate-specific imaging agents for Alzheimer's disease. Nucl. Med. Biol. 29 (2002) 633-642
93. 11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease. Nucl. Med. Biol. 30 (2003) 565-571
94. Price D.L., and Sisodia S.S. Mutant genes in familial Alzheimer's disease and transgenic models. Annu. Rev. Neurosci. 21 (1998) 479-505
95. Price J.L. Diagnostic criteria for Alzheimer's disease. Neurobiol. Aging 18 (1997) S67-S70
96. Puchtler H., and Sweat F. Amidoblack as a stain for hemoglobin. Arch. Pathol. 73 (1962) 245-249
97. Robinson S.R., Bishop G.M., and Munch G. Alzheimer vaccine: Amyloid-beta on trial. Bioessays 25 (2003) 283-288
98. 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex. Proc. Natl. Acad. Sci. USA 92 (1995) 10227-10231
99. 13C-labeled styrylbenzene derivatives for detecting brain amyloid plaques. Eur. J. Med. Chem. 39 (2004) 573-578
100. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., and Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the pharmacodynamicAPP mouse. Nature 400 (1999) 173-177
101. Schenk D., Games D., and Seubert P. Potential treatment opportunities for Alzheimer's disease through inhibition of secretases and Abeta immunization. J. Mol. Neurosci. 17 (2001) 259-267
102. Schenk D.B., Seubert P., Lieberburg I., and Wallace J. beta-Peptide immunization: A possible new treatment for Alzheimer disease. Arch. Neurol. 57 (2000) 934-936
103. Schmidt M.L., Schuck T., Sheridan S., Kung M.P., Kung H., Zhuang Z.P., Bergeron C., Lamarche J.S., Skovronsky D., Giasson B.I., Lee V.M., and Trojanowski J.Q. The fluorescent Congo red derivative, (trans, trans)-1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB), labels diverse beta-pleated sheet structures in postmortem human neurodegenerative disease brains. Am J. Pathol. 159 (2001) 937-943
104. Selkoe D.J. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann. NY Acad. Sci. 924 (2000) 17-25
105. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 298 (2002) 789-791
106. Shi J., Perry G., Berridge M.S., Aliev G., Siedlak S.L., Smith M.A., La Manna J.C., and Friedland R.P. Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice. J. Nucl. Med. 43 (2002) 1044-1051
107. Shields A.F., Grierson J.R., Dohmen B.M., Machulla H.J., Stayanoff J.C., Lawhorn-Crews J.M., Obradovich J.E., Muzik O., and Mangner T.J. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat. Med. 4 (1998) 1334-1336
108. Shields A.F., Mankoff D.A., Link J.M., Graham M.M., Eary J.F., Kozawa S.M., Zheng M., Lewellen B., Lewellen T.K., Grierson J.R., and Krohn K.A. Carbon-11-thymidine and FDG to measure therapy response. J. Nucl. Med. 39 (1998) 1757-1762
109. Shimadzu H., Suemoto T., Suzuki M., Shiomitsu T., Okamura N., Kudo Y., and Sawada T. A novel probe for imaging amyloid-β: Synthesis of F-18 labelled BF-108, an acridine orange analog. J. Labelled Comp. Radiopharm. 46 (2003) 765-772
110. Shoghi-Jadid K., Small G.W., Agdeppa E.D., Kepe V., Ercoli L.M., Siddarth P., Read S., Satyamurthy N., Petric A., Huang S.C., and Barrio J.R. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am. J. Geriatr. Psychiatry 10 (2002) 24-35
111. Skovronsky D.M., Zhang B., Kung M.P., Kung H.F., Trojanowski J.Q., and Lee V.M. In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 97 (2000) 7609-7614
112. Styren S.D., Hamilton R.L., Styren G.C., and Klunk W.E. X-34, a fluorescent derivative of Congo red: A novel histochemical stain for Alzheimer's disease pathology. J. Histochem. Cytochem. 48 (2000) 1223-1232
113. Suemoto T., Okamura N., Shiomitsu T., Suzuki M., Shimadzu H., Akatsu H., Yamamoto T., Kudo Y., and Sawada T. In vivo labeling of amyloid with BF-108. Neurosci. Res. 48 (2004) 65-74
114. Trojanowski J.Q., Clark C.M., Schmidt M.L., Arnold S.E., and Lee V.M. Strategies for improving the postmortem neuropathological diagnosis of Alzheimer's disease. Neurobiol. Aging 18 (1997) S75-S79
115. Tubis M., Blahd W.H., and Nordyke R.A. The preparation and use of radioiodinated Congo red in detecting amyloidosis. J. Am. Pharm. Assoc. 49 (1960) 422-425
116. Vavere A.L., and Lewis J.S. Imaging the effects of anti-angiogenic treatments. Q. J. Nucl. Med. 47 (2003) 163-170
117. Vecchio S.D., Ciarmiello A., Potena M.I., Carriero M.V., Mainolfi C., Botti G., Thomas R., Cerra M., D' Aiuto G., Tsuruo T., and Salvatore M. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. Eur. J. Nucl. Med. 24 (1997) 150-159
118. 11C]SB-13 PET. Am. J. Geriatr. Psychiatry 12 (2004) 584-595
119. Walker L.C., Price D.L., Voytko M.L., and Schenk D.B. Labeling of cerebral amyloid in vivo with a monoclonal antibody. J. Neuropathol. Exp. Neurol. 53 (1994) 377-383
120. Walker R.C., Purnell G.L., Jones-Jackson L.B., Thomas K.L., Brito J.A., and Ferris E.J. Introduction to PET imaging with emphasis on biomedical research. Neurotoxicology 25 (2004) 533-542
121. Walker R.C., and Zigler S.S. PET practice in nuclear pharmacy. J. Am. Pharm. Assoc. (Wash) 43 (2003) S42-S43
122. Walsh D.M., Klyubin I., Fadeeva J.V., Rowan M.J., and Selkoe D.J. Amyloid-beta oligomers: Their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans. 30 (2002) 552-557
123. Wang Y., Klunk W.E., Debnath M.L., Huang G.F., Holt D.P., Shao L., and Mathis C.A. Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease. J. Mol. Neurosci. 24 (2004) 55-62
124. Wang Y., Klunk W.E., Huang G.F., Debnath M.L., Holt D.P., and Mathis C.A. Synthesis and evaluation of 2-(3′-iodo-4′-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in Alzheimer's disease. J. Mol. Neurosci. 19 (2002) 11-16
125. Wang Y., Mathis C.A., Huang G.F., Debnath M.L., Holt D.P., Shao L., and Klunk W.E. Effects of lipophilicity on the affinity and nonspecific binding of iodinated benzothiazole derivatives. J. Mol. Neurosci. 20 (2003) 255-260
126. 11C-labelling of (E,E)-1-(3′,4′-dihydroxystyryl)-4-(3′-methoxy-4′-hydroxystyryl) benzene for PET imaging of amyloid deposits. J. Labelled Comp. Radiopharm. 45 (2002) 647-664
127. Weber W.A., Haubner R., Vabuliene E., Kuhnast B., Wester H.J., and Schwaiger M. Tumor angiogenesis targeting using imaging agents. Q. J. Nucl. Med. 45 (2001) 179-182
128. Wengenack T.M., Curran G.L., and Poduslo J.F. Targeting Alzheimer amyloid plaques in vivo. Nat. Biotechnol. 18 (2000) 868-872
129. Wu D., and Pardridge W.M. Pharmacokinetics and blood-brain barrier transport of an anti-transferrin receptor monoclonal antibody (OX26) in rats after chronic treatment with the antibody. Drug Metab. Dispos. 26 (1998) 937-939
130. Wu D., Yang J., and Pardridge W.M. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J. Clin. Invest. 100 (1997) 1804-1812
131. Zhen W., Han H., Anguiano M., Lemere C.A., Cho C.G., and Lansbury Jr. P.T. Synthesis and amyloid binding properties of rhenium complexes: Preliminary progress toward a reagent for SPECT imaging of Alzheimer's disease brain. J. Med. Chem. 42 (1999) 2805-2815
132. Zhuang Z.P., Kung M.P., Hou C., Plossl K., Skovronsky D., Gur T.L., Trojanowski J.Q., Lee V.M., and Kung H.F. IBOX(2-(4′-dimethylaminophenyl)-6-iodobenzoxazole): A ligand for imaging amyloid plaques in the brain. Nucl. Med. Biol. 28 (2001) 887-894
133. Zhuang Z.P., Kung M.P., Hou C., Skovronsky D.M., Gur T.L., Plossl K., Trojanowski J.Q., Lee V.M., and Kung H.F. Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. J. Med. Chem. 44 (2001) 1905-1914
134. Zhuang Z.P., Kung M.P., Wilson A., Lee C.W., Plossl K., Hou C., Holtzman D.M., and Kung H.F. Structure-activity relationship of imidazo[1,2-a]pyridines as ligands for detecting beta-amyloid plaques in the brain. J. Med. Chem. 46 (2003) 237-243